Short answer
Viatris (VTRS) filed its fiscal 2025 10-K annual report with the SEC on Feb 26, 2026. It reported revenue of $14.3B (−3.0% year over year) and net income of −$3.5B.
- Top risk flagged: FDA warning letter & import alert on Indore, India oral dose facility restricting U.S. distribution, with unrecovered revenue impact in FY2025
FY2025 key financial metrics · XBRL
- Revenue
- $14.3B
- −3.0% YoY
- Net income
- −$3.5B
- −454.2% YoY
- Operating margin
- -18.7%
- −18.8 pp YoY
- Gross margin
- 35.2%
- −3.1 pp YoY
- EPS (diluted)
- −$3.00
- −466.0% YoY
- ROE
- -23.9%
- −20.5 pp YoY
- Operating cash flow
- $2.3B
- +0.6% YoY
Source: XBRL data from the Viatris (VTRS) FY2025 10-K on SEC EDGAR. USD.
Viatris FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Global pharma company delivering generics, branded generics, and innovative medicines to ~1B patients across 165+ countries with 30,000+ employees and 27 manufacturing sites
- Five positive Phase 3 readouts in 2025: meloxicam acute pain, low-dose estrogen patch (FDA action target July 30, 2026), LYNX-2 night driving (MR-142), VEGA-3 presbyopia (MR-141, FDA action H2 2026), and EFFEXOR Japan GAD
- EWSR launched 2025: up to ~10% global workforce reduction, $700M–$850M in restructuring charges, targeting $600M–$700M in savings once fully implemented
- 2025 total revenues $14.30B; returned >$1B to shareholders (~$500M buybacks + $561M dividends) despite divestiture headwinds and Indore FDA warning letter impact
- Acquired Aculys Pharma (Oct 2025) for Japan-exclusive rights to pitolisant (narcolepsy/sleep apnea) and Spydia® Nasal Spray: sharpest pivot yet toward patent-protected innovative assets in Japan
Management Discussion & Analysis
- Revenue $14.30B, down 3% YoY ($439M decline); Indore facility impact ~$370M drag; Greater China only growth segment, +8% to $2.33B
- Gross margin 35% vs 38%; adjusted gross margin 56% vs 58%; operating loss $(2.66B) vs near-breakeven $10M in 2024, driven by $2.94B goodwill impairment
- Best segment: Greater China +8% constant currency; worst: JANZ -11% ($152M decline) from government price cuts and Indore impact
- Operating cash flow $2.32B (up $13M YoY); capex $378.8M; buybacks $500.5M; dividends $561.2M; 2026 capex guided $350M–$450M
- 2026 restructuring program targets $600M–$700M savings, $700M–$850M pre-tax charges; Nashik plant fire (Feb 2026) adds supply risk; biosimilar non-compete expiry unlocks new revenue opportunity
Risk Factors
- FDA warning letter & import alert on Indore, India oral dose facility restricting U.S. distribution, with unrecovered revenue impact in FY2025
- U.S. tariffs on pharmaceutical imports (including API) threatening cost structure; competitors may be disproportionately less affected
- Top 3 customers ~25% of net sales; limited manufacturing sites plus post-divestiture API supply dependence on single external vendor
- Inflation Reduction Act (2022) drug price negotiation and most-favored-nation pilot programs risk compressing innovative pipeline product margins
- Significant indebtedness with refinancing risk at higher rates; $2.94B goodwill impairment charge taken in 2025
Generated from the filing text; verify against the original. How to read a 10-K
Other Viatris annual reports
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.